ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Inclusion Criteria:

1. At least age of 18 years at screening. 2. Patients，who have progressed on orintolerant to standard therapie，with histologically confirmedrecurrent/metastatic HNSCC or other solid tumor.

2. At least one measurable lesion according to RECIST 1.1. 4. Agree to providefresh or archival tumor tissue and peripheral blood samples.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~1. 6. Lifeexpectancy >= 12 weeks. 7. Men or women should be using adequate contraceptivemeasures throughout the study.

4. Female subjects must not be pregnant at screening or have evidence ofnon-childbearing potential.

5. Signed and dated Informed Consent Form.

Exclusion Criteria:

1. Treatment with any of the following:

2. Previous or current treatment with B7-H3 targeted therapy

3. Any cytotoxic chemotherapy, investigational agents and small molecule targetedtherapy within 14 days prior to the first scheduled dose of HS-20093

4. Prior treatment with macromolecule anti-tumor therapy or other anticancer drugswithin 28 days prior to the first scheduled dose of HS-20093

5. Radiotherapy with a limited field of radiation for palliation within 2 weeks,or patients received more than 30% of the bone marrow irradiation, orlarge-scale radiotherapy within 4 weeks prior to the first scheduled dose ofHS-20093

6. Pleural or peritoneal effusion requiring clinical intervention. Pericardialeffusion

7. Major surgery within 4 weeks of the first dose of HS-20093

8. Spinal cord compression or brain metastases.

9. Treatment with drugs that are predominantly CYP3A4 strong inhibitors orinducers or sensitive substrates of CYP3A4 with a narrow therapeutic rangewithin 7 days of the first dose of study drug; or requiring treatment withthese drugs during the study.

10. Currently receiving drugs known to prolong QT interval or may cause torsade depointe; or requiring treatment with these drugs during the study.

11. Any unresolved toxicities from prior therapy greater than Grade 2 according toCommon Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exceptionof stable hypothyroidism treated with hormone replacement therapy, alopecia orneurotoxicity.

12. History of other primary malignancies. 4. Inadequate bone marrow reserve ororgan dysfunction 5. Evidence of cardiovascular risk. 6. Severe, uncontrolledor active cardiovascular diseases. 7. Diabetes ketoacidosis or hyperglycemiahypertonic occurring within 6 months before the first dose of the study drug,or the glycosylated hemoglobin value ≥ 7.5% in the screening period.

13. Severe or poorly controlled hypertension. 9. Bleeding symptoms with apparentclinical significance or obvious bleeding tendency within 1 months prior to thefirst dose of HS-20093 10. Serious arteriovenous thrombosis events occurredwithin 3 months before the first dose.

14. Severe infections occurred within 4 weeks before the first dose. 12. Patientswho have received continuous steroid treatment for more than 30 days within 30days before the first dose, or need long-term (≥ 30 days) steroid treatment, orwho have other acquired and congenital immunodeficiency diseases, or have ahistory of organ transplantation 13. The presence of active infectious diseaseshas been known before the first dose such as hepatitis B, hepatitis C,tuberculosis, syphilis, or human immunodeficiency virus HIV infection, etc.

15. Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or moresevere cirrhosis.

16. Other moderate or severe lung diseases that may interfere with the detection ortreatment of drug-related pulmonary toxicity or may seriously affectrespiratory function.

17. Previous history of serious neurological or mental disorders, includingepilepsy, dementia or severe depression and any other status that may interferein assessment.

18. Women who are breastfeeding or pregnant or planned to be pregnant during thestudy period.

19. Vaccination or hypersensitivity of any level within 4 weeks prior to the firstdose of HS-20093 19. History of severe hypersensitivity reaction, severeinfusion reaction or allergy to recombinant human or mouse derived proteins.

20. Hypersensitivity to any ingredient of HS-20093. 21. Unlikely to comply withstudy procedures, restrictions, and requirements in the opinion of theinvestigator 22. Any disease or condition that, in the opinion of theinvestigator, would compromise subject safety or interfere with studyassessments